Mabworks ：Obinutuzumab beta approved for marketing in China.
On June 9, the NMPA official website showed that a new indication for Tian Guangshi’s MIL62 (generic name: Obinutuzumab β Injection) has been approved for marketing, for the treatment of primary membranous nephropathy (PMN), making it the world’s first targeted drug approved for this indication.
MIL62 is an innovative third-generation CD20 antibody drug independently developed by Tian Guangshi. It was first approved for marketing in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the world’s first CD20 antibody approved for this disease and the first domestic drug in China for this field. On June 4, 2026, Tian Guangshi entered into a commercial licensing agreement with Everest Medicines, granting Everest the rights for clinical development and commercialization of MIL62 in the Asia-Pacific region (including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong (China), Macau (China), and Taiwan (China)).
Buy Obinutuzumab beta from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
